Introduction
Worldwide, 35 million people are living with HIV-1, and yet only 20% have access to combination anti-retroviral therapy (cART). The use of cART upon daily intake successfully suppresses viral replication, reduces transmission rates of the virus and prolongs life expectancy of infected patients. However, prolonged use of this therapy leads to drug toxicity and viral resistance (Palella et al., 1998) . Furthermore, HIV-1 replication reoccurs upon cART discontinuation even after long term viral suppression, indicating that patient is not cured and that the virus persists in latent viral reservoirs (Wong et al., 1997; Finzi et al., 1999) . Clearly new therapies need to be developed to treat and possibly cure HIV-1 infection (Cohen, 2011) .
Currently, a functional cure from HIV-1 has been achieved in only one patient, after two allogeneic stem-cell transplantations with CD34þ peripheral blood stem cells (Hematopoietic Stem Cells (HSC)) from a donor who lacks expression of HIV-1 coreceptor CCR5, which provided the patient with a new immune system resistant to HIV-1 infection (Hutter et al., 2009; Allers et al., 2011) . Since only o1% of the Caucasians and almost none of the African population are homozygous for the deletion in the CCR5 genome (Dean et al., 1996; Samson et al., 1996; Liu et al., 1996) , an HLA-matched donor lacking a functional CCR5 gene would be difficult to find. However, host cell deprivation of essential HIV-1 co-factors by means of gene therapy might be a promising new treatment option. Numerous RNA and proteinbased gene therapy strategies have been explored to target the host protein CCR5 to block HIV-1 infection (2010; Akkina, 2007, 2008 ). Yet, those CCR5-targeting therapies are not applicable for circumventing infection with CXCR4-using HIV-1 variant (Oberlin et al., 1996) . Furthermore, gene therapy using shRNAs that target highly conserved HIV-1 sequences have been explored (Berkhout, 2009; DiGiusto et al., 2010) . However, targeting HIV directly have been proven ineffective due to rapid turnover and error-prone nature of the virus, the virus could escape by single point mutation in the targeted conserved region (Senserrich et al., 2008) .
The naturally occurring restriction factor, Trim5α (Tripartite interaction motif 5α) has been explored in gene therapy applications against HIV-1 ( Akkina, 2005, 2008) . Trim5α targets the incoming viral capsid to be degraded by a proteasomedependent mechanism, thereby disrupting reverse transcription and blocking infection (Rold and Aiken, 2008; Stremlau et al., 2004) . The antiviral activity of Trim5α protein is species specific. HIV-1 replication is completely blocked by Trim5α protein from rhesus macaque (rhTrim5α) whereas human Trim5α (huTrim5α) only minimally interferes with HIV-1 replication (Stremlau et al., 2004; Sakuma et al., 2007; Rits et al., 2007) . However, amino acid changes in the SPRY (B30.2) domain of the huTrim5α gene can increase the antiviral activity of the protein (Li et al., 2006; Yap et al., 2005; Pham et al., 2010 to be successful in humanized mouse models Akkina, 2005, 2008; Walker et al., 2012) .
Although rhTrim5α seemed to be a good candidate for HIV-1 treatment in a gene therapy setting, the virus might be able to adapt to rhTrim5α due to its high mutation rate as result of lack of proof reading by the reverse transcriptase enzyme. In this study, we have successfully adapted two HIV-1 isolates to replicate in presence of rhTrim5α in in vitro cultures. Escape mutations responsible for escape from rhTrim5α were seen in Gag and polp51 subunit. We have characterized the impact of the escape mutations on the sensitivity of the virus to Trim5α and replication capacity in primary cells.
Results

HIV-1 escaped Trim5α-mediated pressure in vitro
To determine whether HIV-1 can escape from rhTrim5α mediated inhibition, longterm cultures of HIV-1 were performed in cells expressing high levels of rhTrim5α. Two different HIV-1 variants were used: NL4-3 Ba-L (WT) and NL4-3 Ba-L containing four mutations in the capsid protein (L215V, H219Q, A220P, and I223V) (CypA-BR) that have previously been associated with lower sensitivity to human and rhesus Trim5α . Four parallel cultures of U87 expressing CD4 and CCR5 (U87.CD4.CCR5) were inoculated with WT or CypA-BR mutant viruses and the culture supernatants were serially passaged onto mixed cultured of U87.CD4.CCR5 cells highly expressing rhTrim5α (U87.CD4.CCR5 rhTrim5α) and overtime decreasing percentages of U87.CD4.CCR5 cells (Fig. 1) . In cultures inoculated with WT variant, viral replication as reflected by p24 production, strongly decreased when the proportion of U87.CD4.CCR5 rhTrim5α cells was increased to 95-99% (Fig. 1a) . Virus replication remained detectable at lower levels until day 98 after the culture. In culture WT-1, WT-2 and WT-4, low viral replication was observed between day 105 till 133 and a rebound in viral replication was evident at day 147. Interestingly, virus replication in culture WT-3 remained detectable throughout the whole culture period with viral replication peaks at day 112-119 and 147-154. In the cultures inoculated with CypA-BR mutant variant, a similar decrease in viral replication was observed when the proportion of U87.CD4.CCR5 rhTrim5α cells was increased to 50-99% (Fig. 1b) . In culture CBR-1 and CBR-2, a transient increase in viral replication was observed at day 77-84 (CBR-1) or day 98-105 (CBR-2), which was followed by a second increase in viral replication at day 133 that continued throughout the remainder of the culture period. Viral replication in CBR-3 became detectable at day 133 after the onset of the culture, but remained at low levels until day 154 when a clear rebound of viral replication was detected. In viral culture CBR-4, a transient peak in viral replication was observed at day 77-84 and 119, whereas a more continuous replication was observed from day 161 onwards (Fig. 1b) . These data showed that HIV-1 evolved to escape from rhTrim5α-mediated restriction in vitro.
Mutations in gag and pol are associated with escape of HIV-1 from rhTrim5α
Since the Trim5α protein interacts with the incoming viral capsid in the cytoplasm (Rold and Aiken, 2008; Stremlau et al., 2004) , we performed sequence analysis of the gag region of the in vitro evolved rhTrim5α escape variants. RNA was isolated from virus containing supernatant of the in vitro evolved cultures at the end of culturing period. From the in vitro evolved rhTrim5α escape wild type viruses, we observed sequence variations in the matrix (MA) and capsid (CA) domains of the gag region in 3 out of 4 viruses (WT-1, WT-3, and WT-4) ( Table 1 ). In in vitro evolved rhTrim5α escape virus WT-1, we observed 10 mutations in gag, of which 1 amino acid was located in the MA domain and 9 in the CA region (Table 1) . Three of the observed CA mutations (L215M, V218M and H219Q) were located in the CypA-binding region of the viral capsid (Table 1 ). In the WT-3 and WT-4 variants, amino acid changes were only observed in MA domain of the gag region (Table 1) . WT-3 virus harbored the D14N mutation, which neutralized the negative charge of aspartic acid, and E52K resulted in a charge change at that position from negative to positive. Furthermore, the WT-4 virus harbored the E to K mutation at two positions, 12 and 52, in MA which resulted charge change from negative to positive. Additionally, WT-4 contained the V46I and D102N mutation, which neutralized the negative charge at position 102.
From the in vitro evolved CypA-BR mutant viruses, the parental 215V, 219Q, 220P, and 223V mutations in the CypA binding region remained present in all obtained variants. Interestingly, the in vitro evolved viruses had additionally gained only 1 escape mutation each in the CA region, P225S in CBR-1, I261V in CBR-3, and R214K in CBR-4 variant.
It has been demonstrated that mutations in the RT gene influence the viral sensitivity to rhTrim5α (Yang et al., 2013) . Indeed we observed mutations in the pol-p51 subunit in five of the in vitro evolved rhTrim5α escape variants. Although most amino acid changes were unique for a single in vitro evolved variant, substitutions I244M, and N255D (which resulted in change of amino acid charge) were observed in WT-1 and WT-4 variants. Gain of positively charged amino acid was observed in in vitro evolved variants WT-1, WT-2 and WT-4 (E248K, Q102K, and E53K, respectively). In the in vitro evolved variants progeny of CypA-BR parental virus, we observed 2 mutations in the pol-p51 subunit of CBR-1, whereas 6 mutations in this region were observed in CBR-3. Interestingly, amino acid substitutions Q102K, and K122E in CBR-3 resulted in changes in amino acid charge. Our data showed that HIV-1 escape from rhTrim5α-mediated inhibition resulted in substitutions in gag and pol region of the virus.
Escape variants from rhTrim5α in vitro have altered sensitivity to different huTrim5α variants
To determine whether mutations in gag and pol gained in the in vitro evolved rhTrim5α escape variants affect viral sensitivity to different huTrim5α variants, we infected U87.CD4.CCR5 cell lines stably expressing rhTrim5α, huTrim5α or modified huTrim5α (carrying the R332P or R335G amino acid change) with increased antiviral activity (Li et al., 2006; Yap et al., 2005; Pham et al., 2010) with 100TCID 50 of the different viruses. Replication of the parental viruses WT and CypA-BR was inhibited in cells expressing Trim5α proteins when compared to the non-transduced cells (supplementary Table 1 ). All in vitro evolved rhTrim5α escape variants were able to infect huTrim5α expressing cells more efficiently when compared to non-transduced cells (Supplementary Table 1 ).
The parental WT virus could efficiently be inhibited by the rhTrimα, huTrimα R332P and huTrimα R335G proteins (Table 2) , with virus production levels o30% in comparison to virus replication in presence of huTrim5α. Furthermore, all 4 in vitro evolved WT viruses could still be inhibited by rhTrim5α (Table 2 ). The in vitro evolved variants lost sensitivity to huTrim5α R332P and R335G mediated inhibition ( Table 2) .
The parental CypA-BR virus was inhibited by rhTrim5α, huTrim5α R332P and huTrim5α R335G proteins and showed o45% of virus production in presence of these Trim5α variants in comparison to huTrim5α ( Table 2 ). The four in vitro evolved Trim5α escape variants obtained from CypA-BR virus could still be inhibited by rhTrim5α (Table 2 ). However, these viruses lost sensitivity to the antiviral activity of modified huTrim5α variants (R332P and R335G) when compared to the parental CypA-BR virus (Table 2) .
Next, we analyzed whether localization of mutations in different regions of the viral genome gained during escape from rhTrim5α pressure affect virus sensitivity to rhTrim5α and modified huTrim5α proteins. We divided the viruses into three groups, with mutations only observed in gag region (including the CBRparental virus with 4 mutations in gag), pol-p51 region or both in gag-pol-p51 regions. The WT virus was used as a reference virus (no mutation). The relative (to huTrim5α) infectivity of the viruses in the presence of rhTrim5α and modified huTrim5α were compared. Increased virus replication was observed in the presence of modified huTrim5α proteins irrespective of the location of the mutations (Fig. 2) .
Trim5α sensitivity of viruses with escape mutations in CA
Our data suggest that mutations in the different viral proteins (Gag and Pol-p51) affect viral sensitivity to rhTrim5α and modified huTrim5α proteins. Since Trim5α is known to interact with the viral capsid, we assessed the role of the observed mutations in CA in the in vitro evolved rhTrim5α variants in altering virus sensitivity to Trim5α. We introduced different combinations of the observed of escape mutations in CA into the backbone of full length replicating NL4-3 BAL (WT and CypA-BR) viruses (Table 3) and analyzed the effect these mutations on Trim5α mediated inhibition.
In contrast to the parental viruses, all derivative rhTrim5α escape variants were able to infect huTrim5α expressing cells more efficiently than the non-transduced cells (supplementary Table 1 ). The rhTrim5α protein was able to inhibit all derivative variants from the parental WT virus (Table 4) . Additionally, all the WT derivative viruses became insensitive to both modified huTrim5α variants (R332P and R335G) mediated inhibition ( Table 4 ). The huTrim5α R332P variant was unable to block replication of WT-E, whereas the other WT derivative viruses could still be partial inhibited by this protein. Furthermore, WT-D and WT-E almost completely lost sensitivity for huTrim5α R335G mediated inhibition, while the other WT derivative viruses were partially inhibited by this protein.
Of the viral variants derived from the parental CypA-BR mutant virus, CBR-C became relative insensitive to rhTrim5α and completely lost sensitivity to modified huTrim5α proteins, while replication of CBR-A and CBR-B was partially inhibited by both modified huTrim5α proteins (Table 4) .
Replication capacity of rhTrim5α escape variants in primary PBMC
Next, we investigated whether escape from rhTrim5α-mediated restriction affects viral replication capacity in primary cells. PHA-stimulated PBMCs were inoculated with (100TCID 50 ) in vitro evolved rhTrim5α escape variants and derivative mutant viruses and virus production was analyzed with p24 ELISA every day for a period of 18 days. Virus production at day 11 was compared to that of the parental viruses (WT and CypA-BR). Our data showed that one out of 4 in vitro evolved rhTrim5α escape derived from WT virus (WT-1), which harbored 9 and 4 amino acid mutations in Gag and p51 RT subunit respectively, showed an increased viral replication capacity as compared to the WT parental virus (Fig. 3a) . The derivative mutant variants WT-A, WT-D and WT-E showed significantly lower virus replication capacity when compared to the WT parental virus (Fig. 3a) .
Two out of 4 of the in vitro evolved rhTrim5α escape variants derived from the CypA-BR mutant virus (CBR-1 and CBR-2) showed an increased viral replication capacity in PBMC whereas 1 out of 4 in vitro evolved viruses (CBR-3, with 6 mutations in p51 RT domain) showed a decreased viral replication capacity at day 14 in comparison to the parental CypA-BR virus (Fig. 3b) . Interestingly, derivative mutant variants derived from the CypA-BR mutant virus (CBR-A, CBR-B, and CBR-C) carrying only the R214K, P225S or I261V mutations in Gag did not alter virus replication in primary PBMCs. These data suggest that mutations in gag and polp51 gained during escape from rhTrim5α-pressure may alter viral replication capacity in primary PBMCs.
Discussion
Although gene therapy approaches using the antiviral Trim5α protein are very promising for HIV-1 gene therapy Akkina, 2005, 2008; Walker et al., 2012) , it is also very likely that this approach might eventually be hampered by the development of viral escape mutations. Indeed, we and others have already demonstrated that mutations in the viral determinant involved in Trim5α restriction, which is located in the CypA binding region of the HIV-1 capsid, can develop during natural HIV-1 infection and interfere with the sensitivity of the virus to Trim5α Chatterji et al., 2005; Ikeda et al., 2004; Kootstra et al., 2007) .
Here, we showed that HIV-1 was able to escape from rhTrim5α-mediated inhibition in vitro which is in agreement with previous findings (Pacheco et al., 2010; Sollet al., 2013; Chatterji et al., 2005) . We have identified 12 mutations in capsid that were associated to escape of the NL-4-3 Ba-L virus from rhTrim5α-mediated inhibition. Four out of 9 mutations were located in the CypA-binding region of the viral capsid (L215M, V218M, H219Q and P225S). Three mutations (V218M, H219Q, M228I) were found in vivo in previous reports (Chatterji et al., 2005; Kootstra et al., 2007) . Additionally, mutations T242N and G248A found in one of the escape variants, were previously reported as viral escapes from HLA-B57 restricted CTL pressure, viruses harboring these mutations have reduced viral fitness and increased sensitivity for huTrim5α (Granier et al., 2013; Gijsbers et al., 2013) . Our data showed that derivative virus carrying only T242N and G248A escape mutations were still sensitive to rhTrim5α to same level of the WT-parental virus, but almost completely abolished restriction from modified huTrim5α proteins, with cost of viral fitness in primary PBMCs. Furthermore, when other escape mutations were added into the combination, particularly in the CypA-binding region of the viral capsid, sensitivity to modified huTrim5α proteins were decreased but not to the level of sensitivity in virus carrying only the T242N and G248A mutations. Our data is in agreement with previous findings that the presence of these escape mutations in the capsid region have reduced viral sensitivity to Trim5α variants and altered viral fitness in primary PBMCs (Granier et al., 2013) . Interestingly, the mutations described here might also be beneficial for the development of lentiviral vectors for gene therapy and these mutations might be able to enhance transduction efficiency of the lentiviral vector in certain cell types.
Although escape mutations from rhTrim5α were mostly reported to occur in the viral capsid Chatterji et al., 2005; Ikeda et al., 2004; Kootstra et al., 2007) , we observed 6 amino acid changes (E12K, D14N, V46I, E52K, D102N, and S126N) in the matrix domain of Gag. Our findings added to a previous study that described R20W and S126R mutations in MA as escapes from rhTrim5α in vitro (Pacheco et al., 2010) , however these mutations were not observed in our study. The only in vitro evolved rhTrim5α-escape variant (WT-3) with mutations strictly in MA region (D14N and E52K) was still sensitive to rhTrim5α, whereas sensitivity to inhibition by the modified huTrim5α variants was completely abolished (R332P) or strongly decreased (R335G). The WT-4 variant containing MA mutations as well as mutations in the pol-p51 regions, showed a similar Trim5α sensitivity pattern as WT-3, suggesting that mutations in MA alone or in combination with pol-p51 contribute to escape from Trim5α-mediated inhibition.
Previously, we demonstrated that mutations in the HIV-1 capsid (L215V, H219Q, A220P, and I223V) were able to abrogate post-entry block in simian cells , allowing efficient lentiviral transduction in those cells (Rits et al., 2007) . Our data showed that HIV-1 variant carrying the four mutations (CypA-BR) remained sensitive to rhTrim5α when the protein was overexpressed in U87.CD4.CCR5 cells. Moreover, adaptation of the CypA-BR mutant virus from the overexpressed rhTrim5α protein was achieved after 120 days of culture and only resulted in 1 additional mutation in viral capsid per escape variant (R214K, P225S, or I261V) in three out of four cultures. Interestingly, our derivative mutants data showed that presence of the additional single escape mutation in Gag indeed reduced viral sensitivity to Trim5α variants but did not cause any changes in viral fitness. In the in vitro evolved CBR-2 variant, no escape mutations in gag nor pol-p51 genes was observed, however the virus had clearly adapted to the presence of the different Trim5α proteins as compared to the parental virus was observed. This suggests that viral adaptation might also occur in other regions of the virus that have not yet been associated with Trim5α resistance.
Recently it has been demonstrated that inhibition of reverse transcription resulted in an increase of viral core stability (Yang et al., 2013) and this might also affect sensitivity of the virus to Trim5α mediated inhibition. In our study, we observed amino acid changes in the p51 RT subunit region in the Pol protein in 5 out of 8 in vitro evolved rhTrim5α escape variants. Indeed, mutations in pol-p51 (A26T, G196R, R206G, and E296K) have previously been associated to escape from rhTrim5α, in which 3 out of 4 resulted in change of amino acid charge (Pacheco et al., 2010) . Here, we observed that an in vitro evolved rhTrim5α escape variant derived from WT virus (WT-2) with only a Q102K mutation in the pol-p51 subunit also has reduced viral sensitivity to Trim5α-mediated inhibition and maintained viral fitness. In the in vitro evolved rhTrim5α escape variant derived from the CypA-BR mutant virus (CBR-1), the V21I and T200A mutations in pol-p51 subunit rendered the virus less sensitive to huTrim5α R332P in comparison to virus with only P225S CA mutation (CBR-A). Collectively, our findings confirm that changes in RT contribute to viral sensitivity to rhTrim5α.
We did not observe complete abolishment of rhTrim5α restriction of the in vitro rhTrim5α escape variants, confirming previous observations by others (Soll et al., 2013) . Furthermore, we observed that the region of the viral genome in which the escape mutations were located, did not necessarily dictate viral sensitivity to rhTrim5α. Indeed, we were able to gain an escape variant from rhTrim5α only after at least 119 days of culture in cells expressing high levels of rhTrim5α protein, which was more than double the time needed for a CCR5 tropic HIV-1 to evolve into a CXCR4-using variant in vitro (Edo-Matas et al., 2011) . Plausibly, a synergy of several mutations in both gag and pol regions of the virus is essential to provide an optimal viral capsid stability and rate of reverse transcription for efficient abolishment of rhTrim5α-mediated restriction. Our data contributes to the theory that complete escape from rhTrim5α is difficult to achieve, since the changes in virus are observed in gag and reverse transcriptase, which are very conserved regions. The introduction of just a single mutation that allows viral escape may have severe consequences for viral fitness and require compensatory mutations for optimal viral replication in the presence of the restriction factor (Pacheco et al., 2010) .
Additionally, we have demonstrated that viruses with escape mutations from rhTrim5α have become less sensitive to or completely abolished restriction by modified huTrim5α R332P and R335G proteins, in agreement with findings by others (Maillard et al., 2011; Veillette et al., 2013; Soll et al., 2013) . Overall, HIV-1 variants studied here seemed to be more sensitive to the antiviral activity of the modified huTrim5α R335G variant in comparison to the R332P variant.
Moreover, 8 out of the 9 rhTrim5α escape mutations in Gag (I147V, V159I, L215M, V218M, H219Q, M228I, T242N and G248A) were previously associated with escape from HLA-B57 restricted CTL pressure (Gijsbers et al., 2013; Bailey et al., 2008; Navis et al., 2007; Jansen et al., 2005) . This finding supports previous observations that Trim5α links innate and adaptive immunity, and that viral sensitivity to Trim5α determines susceptibility to HLA-B57 CTL pressure (Battivelli et al., 2011; Granier et al., 2013) .
Conclusions
Our findings showed that HIV-1 can escape from rhTrim5α-mediated inhibition by gaining escape mutations in viral capsid, matrix and reverse transcriptase genes. The in vitro development of these different combinations of mutations took more than 119 days, suggesting that mutations supporting viral escape from rhTrim5α, in these conserved regions require compensatory mutations to maintain viral fitness.
Materials and method
Cell isolation and cultures
PBMC's were isolated from buffy coats of healthy blood donors. Written informed consents were obtained from all donors in accordance with the ethical principles set out in the declaration of Helsinki. This study was approved by the Medical Ethics Committee of the Academic Medical Center and the Ethics Advisory Body of the Sanquin Blood Supply Foundation in Amsterdam, The Netherlands. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using Lymphoprep (Axis-Shield, Olso, Norway) density gradient centrifugation, pooled and cryopreserved. After thawing, the PBMC pool was stimulated for three days in Iscoves' Modified Dulbecco's Medium (IMDM) supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 mg/ml ciproxin (Bayer, Mijdrecht, The Netherlands) and 1 mg/ml phytohaemagglutinin (PHA; Remel Europe, Dartford, England, UK) at a cell density of 5 Â 10 6 cells/ml in a humidified 10% CO 2 incubator at 37°C. PBMC cultures were continued in IMDM supplemented with 10% FCS, 20 U/ml recombinant interleukin 2 (rIL2; Chiron Benelux, Amsterdam, The Netherlands, 5 mg/ml polybrene (Sigma, Zwijndrecht, The Netherlands), 100 U/ml penicillin and 100 mg/ml streptomycin at a cell density of 1 Â 10 6 /ml in a humidified 10% CO 2 incubator at 37°C. HEK-293 T cells (ATCC) were cultured in Dulbecco Modified Eagle's Medium (DMEM) supplemented with 10% heat inactivated fetal calf serum (FCS) and penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C humidified atmosphere supplemented with 10% CO 2 . U87 cell lines stably expressing CD4 and wild-type CCR5 co-receptor (a gift from Liselotte Antonsson, Lund University) and TZMbl cells (a gift from DC Montefiore, Duke University Medical Centre) were cultured in IMDM supplemented with 10% fetal calf serum (FCS) and penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C humidified atmosphere supplemented with 10% CO 2 .
Generation of cells stably expressing Trim5α variants
Trim5α variants (human, rhesus, human R332P and human R335G) were cloned into a lentiviral vector (LV) construct carrying CAG promoter and GFP . HIV-1 based lentiviruses expressing the Trim5α variants were produced by calcium phosphate transfection of 293 T cells with the lentiviral vector (LV) construct, the packaging construct for gag/pol, vesicular stomatitis virus glycoprotein envelope (pCMV-VSV-G) and rev (pRSV-rev) as described previously (Dull et al., 1998) . Infectious LVs were harvested at 48 and 72 h after transfection and filtered through a 0.22 μm filter. The LVs were concentrated by ultracentrifugation (2 h at 50,000 g). Virus titers were quantified by determination of the 50% tissue culture infectious dose (TCID50) on 293 T cells. After 24 h, the infected cells were analyzed by FACS. Next, the produced lentiviruses were used to transduce U87.CD4.CCR5 cells (MOI¼ 20) . Transduction efficiency were analyzed by FACS and western blot.
Virus productions
For the production of replicating NL4-3 Bal clones, the full length HIV-1 constructs (containing wild type and CypA-BR capsids) were transfected into 293 T cells using the calcium phosphate method. Viruses were harvested at 48 and 72 h after transfection and filtered through a 0.22 μm fiter. Virus titers were quantified by determination of the TCID50 on luciferase reporter TZMbl cells. After 48 h, luciferase substrate (0.83 mM ATP, 0.83 mM D-luciferin (Duchefa Biochemi BV), 18.7 mM MgCl 2 , 0.78 μM Na 2 H 2 P 2 O 7 , 38.9 mM Tris-HCl pH 7.8, 0.39% glycerol, 0.03% Triton X-100, and 2.6 μM dithiothreitol) was added and luminescence was measured for 1 second per well using the Centro LB 960 (Berthold technologies).
VSV-G pseudotyped single round luciferase viruses were produced by cotransfection of pNL4-3.Luc.R-E-constructs containing wild type or the CypA-BR mutant capsids (which were placed in the pNL4-3.Luc.R-E-construct by site directed mutagenesis) and the pCMV-VSV-G in 293 T cells using the calcium phosphate method. Infectious viruses were harvested at 48 and 72 h after transfection and filtered through a 0.22 μm filter. Virus titers were quantified by determination of the TCID50 on 293 T cells. After 48 h, infected cells were washed with PBS and luciferase substrate was added and luminescence was measured.
HIV-1 variants containing mutations in the capsid protein was constructed as previously described (Gijsbers et al., 2013) . For the production of replicating NL4-3 Bal clones containing the desired mutations, the mutated gag insert was ligated into the full length molecular NL4-3 Bal clone using In-Fusion s HD Cloning kit as described by the manufacturer (Clontech s Laboratories, Inc.). The full length NL4-3 Bal molecular clones were then transfected into 293 T using the calcium phosphate method. Virus production from the 293 T cells was analyzed at day 3 and 7 after transfection using an in house p24 ELISA (Tersmette et al., 1989) . Virus stocks were grown on PHA-stimulated PBMC and virus titers were quantified by determination of the TCID50 on luciferase reporter TZMbl cells. The gag regions of the obtained viruses were sequenced as previously described to confirm the introduction of mutations (Gijsbers et al., 2013) .
In vitro evolution of HIV-1 to abolish rhTrim5α-mediated pressure
To obtain HIV-1 variants which are resistant to rhTrim5α-mediated pressure, we used an adjusted protocol which was previously described (Edo-Matas et al., 2011) . Six parallel cultures of 4 Â 10 4 U87.CD4.CCR5 cells per well plated in a 24-well tissue culture plate were inoculated with 1000TCID 50 of NL4-3 Bal (carrying wild type or CypA-BR capsids). Every week, the viral supernatant was transferred into fresh co-cultures of U87.CD4. CCR5 cells and U87.CD4.CCR5 expressing rhTrim5α cells in which percentages was increased over time (30%, 50%, 70%, 90%, 97% and 99% at weeks 1, 2, 3, 4, 5, and 6 respectively). Subsequently, virus production was monitored weekly by an in house p24 ELISA (Tersmette et al., 1989) .
Infections
To test the antiviral activity of the different Trim5α variants, U87.CD4.CCR5 cells lines stably expressing a Trim5α variant were cultured in a 96-well white plates (Nunc, Langenselbold, Germany) at a density of 8 Â 10 3 cells per well, and inoculated at day 1 with 50, 100 and 200 TCID 50 of NL4-3 luciferase virus strain. After 48 h, the infected cells were washed with PBS and luciferase substrate was added and luminescence was measured. For infection of replicating NL4-3 BAL viruses with mutations in gag region, U87.CD4.CCR5 cell lines stably expressing a Trim5α variant were cultured in a 96-well tissue culture plates (Nunc, Langenselbold, Germany) at a density of 8 Â 10 3 cells per well, and inoculated at day 1 with 200TCID 50 of the virus. 24 h post inoculation, unbound virus particles were washed with medium. At 3 and 7 days post inoculation, virus production was determined using an in-house p24 ELISA. Statistical analysis were done using GraphPad Prism version 5.01 for Windows. To determine the viral replication rates of HIV-1 variants, 2 Â 10 6 PHA-stimulated pooled PBMC were inoculated with 100TCID50 per virus variant for 2 h at 37°C in a shaking water bath in a total volume of 1,5 ml. Subsequently, the inoculated PBMC were washed with 5 ml of IMDM supplemented with 10% FCS, and cultured in IMDM supplemented with 10% FCS, 20 U/ml rIL2, 5 mg/ml polybrene, 100 U/ml penicillin and 100 mg/ml streptomycin (PBL medium) at a cell density of 1 Â 10 6 per ml in a humidified 10% CO 2 incubator at 37°C. On day 5,8,11 and 14 after inoculation, 1 Â 10 6 fresh PHA-stimulated pooled PBMC in 1 ml of PBL medium were added to the cultures. Samples for determination of p24 antigen production were harvested every day after inoculation. All samples were tested for p24 antigen production simultaneously at the end of the experiment using an in-house p24 ELISA (Tersmette et al., 1989) . Statistical analysis were done using GraphPad Prism version 5.01 for Windows.
DNA isolation, PCR and sequencing
Total DNA was isolated from infected cells using a modification of the L6 isolation method (Kootstra and Schuitemaker, 1999) . Gag PCR amplification was performed as previously described (Gijsbers et al., 2013; Navis et al., 2008) . Pol PCR amplification was performed with PCR using primers Pol outer fw (5 0 -GGAAGGACACCAAATGAAAG-3 0 ) and Pol outer rv (5 0 -CCTTAGCTTTCCTTG-3 0 ) and a nested PCR with primers Pol start fw (5 0 -GTACTGAGAGACAGGCTAAT-3 0 ) and Pol end rv (5 0 -GGTGTTTTACTAATCTTTTCCATGTG-3 0 ) using the GoTaq polymerase kit (Promega) and the following amplification cycles: 5 min 30 s 94°C, 30 cycles of 45 s 94°C, 30 s 50°C, 3 min 72°C, followed by a 10 min extension at 72°C and subsequent cooling at 4°C. PCR products were purified using ExoSAP-IT (USB) according to the manufacturer's protocol. Sequencing of pol-p51 subunit was performed using BigDye Terminator v1.1 Cycle Sequencing kit (ABI Prism, Applied Biosystems) as previously described (Gijsbers et al., 2013) 
